Tumor microenvironment (TME) significantly affects colorectal cancer (CRC) progression and therapeutic efficacy, particularly the infiltrating stromal components. This study profiled the TME composition of tumor tissue and identify TME-related, especially stroma-related genes having prognosis value in CRC patients.
Materials and Methods:
We used the ESTIMATE algorithm to assess stromal/immune component and divided 524 CRC cases of public dataset into high- and low-score groups. We analyzed the effect of the score on prognosis and extracted the differential expression genes (DEGs) between groups, which were stromal- and/or immune-related genes, and performed a prognostic investigation of the DEGs.
Results:
Higher stromal score correlated with poor survival, whereas the immune score was the inverse. By comparing global gene expression of cases with high vs. low stromal/immune scores, we extracted 474 stroma-related genes, 76 immune-related genes, and 498 intersection genes, which were explored by function enrichment and survival analysis. We identified the expression of five stroma-related genes (including ITGA7, PTPN14, SCG2, TNS1, and GRP) significantly associated with poorer survival, which were validated in the other two independent CRC cohorts.
Conclusion:
These results presented a comprehensive understanding of TME components and identified five stroma-related genes that predict poor outcomes in CRC patients.
Get full access to this article
View all access options for this article.
References
1.
FridmanWH, MillerI, Sautès-FridmanC, et al.Therapeutic targeting of the colorectal tumor stroma. Gastroenterology, 2020; 158:303.
2.
QuailDF, JoyceJA. Microenvironmental regulation of tumor progression and metastasis. Nat Med, 2013; 19:1423.
3.
GalonJ. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science, 2006; 313:1960.
4.
HalamaN, MichelS, KloorM, et al.Localization and density of immune cells in the invasive margin of human colorectal cancer liver metastases are prognostic for response to chemotherapy. Cancer Res, 2011; 71:5670.
5.
RemarkR, AlifanoM, CremerI, et al.Characteristics and clinical impacts of the immune environments in colorectal and renal cell carcinoma lung metastases: Influence of tumor origin. Clin Cancer Res, 2013; 19:4079.
6.
TsujinoT, SeshimoI, YamamotoH, et al.Stromal myofibroblasts predict disease recurrence for colorectal cancer. Clin Cancer Res, 2007; 13:2082.
7.
BarnesTA, AmirE. HYPE or HOPE: The prognostic value of infiltrating immune cells in cancer. Br J Cancer, 2017; 117:451.
8.
TaurielloDVF, Palomo-PonceS, StorkD, et al.TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis. Nature, 2018; 554:538.
9.
BechtE, GiraldoNA, LacroixL, et al.Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biol, 2016; 17:218.
10.
GuinneyJ, DienstmannR, WangX, et al.The consensus molecular subtypes of colorectal cancer. Nat Med, 2015; 21:1350.
11.
CalonA, LonardoE, Berenguer-LlergoA, et al.Stromal gene expression defines poor-prognosis subtypes in colorectal cancer. Nat Genet, 2015; 47:320.
12.
UenoH, KanemitsuY, SekineS, et al.Desmoplastic pattern at the tumor front defines poor-prognosis subtypes of colorectal cancer. Am J Surg Pathol, 2017; 41:1506.
13.
Gonçalves-RibeiroS, Sanz-PamplonaR, VidalA, et al.Prediction of pathological response to neoadjuvant treatment in rectal cancer with a two-protein immunohistochemical score derived from stromal gene-profiling. Ann Oncol, 2017; 28:2160.
14.
WangZ, TangY, TanY, WeiQ, YuW. Cancer-associated fibroblasts in radiotherapy: Challenges and new opportunities. Cell Commun Signal, 2019; 17:47.
15.
HugoW, ZaretskyJM, SunL, et al.Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell, 2016; 165:35.
16.
WangL, SaciA, SzaboPM, et al.EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer. Nat Commun, 2018; 9:3503.
17.
XuWH, XuY, WangJ, et al.Prognostic value and immune infiltration of novel signatures in clear cell renal cell carcinoma microenvironment. Aging (Albany NY), 2019; 11:6999.
18.
PanX-B, LuY, HuangJ-L, LongY, YaoD-S. Prognostic genes in the tumor microenvironment in cervical squamous cell carcinoma. Aging (Albany NY), 2019; 11:10154.
19.
JiaD, LiS, LiD, XueH, YangD, LiuY. Mining TCGA database for genes of prognostic value in glioblastoma microenvironment. Aging (Albany NY), 2018; 10:592.
20.
DengZ, WangJ, XuB, et al.Mining TCGA database for tumor microenvironment-related genes of prognostic value in hepatocellular carcinoma. Biomed Res Int, 2019; 2019:2408348.
21.
MarisaL, de ReynièsA, DuvalA, et al.Gene expression classification of colon cancer into molecular subtypes: Characterization, validation, and prognostic value. PLoS Med, 2013; 10:e1001453.
22.
SmithJJ, DeaneNG, WuF, et al.Experimentally derived metastasis gene expression profile predicts recurrence and death in patients with colon cancer. Gastroenterology, 2010; 138:958.
23.
NishidaN, NagaharaM, SatoT, et al.Microarray analysis of colorectal cancer stromal tissue reveals upregulation of two oncogenic miRNA clusters. Clin Cancer Res, 2012; 18:3054.
24.
YoshiharaK, ShahmoradgoliM, MartínezE, et al.Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun, 2013; 4:2612.
25.
RitchieME, PhipsonB, WuD, et al.limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res, 2015; 43:e47.
26.
YuG, WangLG, HanY, HeQY. ClusterProfiler: An R package for comparing biological themes among gene clusters. Omi A J Integr Biol, 2012; 16:284.
27.
BenjaminiY, HochbergY. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. J R Stat Soc Ser B, 1995; 57:289.
28.
BarettiM, LeDT. DNA mismatch repair in cancer. Pharmacol Ther, 2018; 189:45.
29.
TaniguchiK, KarinM. NF-κB, inflammation, immunity and cancer: Coming of age. Nat Rev Immunol, 2018; 18:309.
30.
WattenbergMM, BeattyGL. Overcoming immunotherapeutic resistance by targeting the cancer inflammation cycle. Semin Cancer Biol, 2020; 65:38.
31.
HayashiT, FujitaK, MatsushitaM, NonomuraN. Main inflammatory cells and potentials of anti-inflammatory agents in prostate cancer. Cancers (Basel), 2019; 11:1153.
32.
GermannM, ZanggerN, SauvainM, et al.Neutrophils suppress tumor-infiltrating T cells in colon cancer via matrix metalloproteinase-mediated activation of TGF β. EMBO Mol Med, 2020; 12:e10681.
33.
ColangeloT, PolcaroG, MuccilloL, et al.Friend or foe?. Biochim Biophys Acta - Rev Cancer, 2017; 1867:1.
Gok YavuzB, GunaydinG, GedikME, et al.Cancer associated fibroblasts sculpt tumour microenvironment by recruiting monocytes and inducing immunosuppressive PD-1 + TAMs. Sci Rep, 2019; 9:3172.
38.
ChiarugiP. Cancer-associated fibroblasts and macrophages. Oncoimmunology, 2013; 2:e25563.
39.
DesgrosellierJS, ChereshDA. Integrins in cancer: Biological implications and therapeutic opportunities. Nat Rev Cancer, 2010; 10:9.
40.
ZhouH, FangY, WeinbergerPM, et al.Transgelin increases metastatic potential of colorectal cancer cells in vivo and alters expression of genes involved in cell motility. BMC Cancer, 2016; 16:55.
41.
HaasTL, SciutoMR, BrunettoL, et al.Integrin α7 is a functional marker and potential therapeutic target in glioblastoma. Cell Stem Cell, 2017; 21:35.
42.
LiuJ, ZhangZ, LiX, et al.Forkhead box C1 promotes colorectal cancer metastasis through transactivating ITGA7 and FGFR4 expression. Oncogene, 2018; 37:5477.
43.
WyattL, Khew-GoodallY. PTP-Pez: A novel regulator of TGFβ signaling. Cell Cycle, 2008; 7:2290.
44.
HanX, SunT, HongJ, et al.Nonreceptor tyrosine phosphatase 14 promotes proliferation and migration through regulating phosphorylation of YAP of Hippo signaling pathway in gastric cancer cells. J Cell Biochem, 2019; 120:jcb.29038.
45.
WyattL, WadhamC, CrockerLA, LardelliM, Khew-GoodallY. The protein tyrosine phosphatase Pez regulates TGFβ, epithelial–mesenchymal transition, and organ development. J Cell Biol, 2007; 178:1223.
46.
SjoblomT, JonesS, WoodLD, et al.The consensus coding sequences of human breast and colorectal cancers. Science (80-), 2006; 314:268.
47.
WangZ, ShenD, ParsonsDW, et al.Mutational analysis of the tyrosine phosphatome in colorectal cancers. Science, 2004; 304:1164.
48.
HottaK, HosakaM, TanabeA, TakeuchiT. Secretogranin II binds to secretogranin III and forms secretory granules with orexin, neuropeptide Y, and POMC. J Endocrinol, 2009; 202:111.
49.
AlrawashdehW, JonesR, DumartinL, et al.Perineural invasion in pancreatic cancer: Proteomic analysis and in vitro modelling. Mol Oncol, 2019; 13:1075.
50.
CourelM, El YamaniF-Z, AlexandreD, et al.Secretogranin II is overexpressed in advanced prostate cancer and promotes the neuroendocrine differentiation of prostate cancer cells. Eur J Cancer, 2014; 50:3039.
51.
BalabanovaS, HolmbergC, SteeleI, et al.The neuroendocrine phenotype of gastric myofibroblasts and its loss with cancer progression. Carcinogenesis, 2014; 35:1798.
52.
HallEH, BalsbaughJL, RoseKL, ShabanowitzJ, HuntDF, BrautiganDL. Comprehensive Analysis of Phosphorylation Sites in Tensin1 Reveals Regulation by p38MAPK. Mol Cell Proteomics, 2010; 9:2853.
53.
ZhouH, ZhangY, WuL, et al.Elevated transgelin/TNS1 expression is a potential biomarker in human colorectal cancer. Oncotarget, 2018; 9:1107.
54.
GhateiMA, JungRT, StevensonJC, et al.Bombesin: Action on gut hormones and calcium in man. J Clin Endocrinol Metab, 1982; 54:980.
55.
LuiVWY, ThomasSM, ZhangQ, et al.Mitogenic effects of gastrin-releasing peptide in head and neck squamous cancer cells are mediated by activation of the epidermal growth factor receptor. Oncogene, 2003; 22:6183.
56.
SaurinJC, Némoz-GaillardE, SordatB, et al.Bombesin stimulates adhesion, spreading, lamellipodia formation, and proliferation in the human colon carcinoma Isreco1 cell line. Cancer Res, 1999; 59:962.
57.
MartínezA, ZudaireE, JuliánM, MoodyTW, CuttittaF. Gastrin-releasing peptide (GRP) induces angiogenesis and the specific GRP blocker 77427 inhibits tumor growth in vitro and in vivo. Oncogene, 2005; 24:4106.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
